Quarterly report pursuant to Section 13 or 15(d)

Severance Charges

v3.10.0.1
Severance Charges
9 Months Ended
Sep. 30, 2018
Restructuring And Related Activities [Abstract]  
Severance Charges

10. SEVERANCE CHARGES

 

As a requirement for the closing of the Arrangement, OncoGenex terminated the employment of one senior executive. Severance payable at the date of the transaction was $1.2 million and has been accounted for in accordance with EITF No. 95-3, “Recognition of Liabilities in Connection with a Purchase Business Combination” as part of the purchase price allocation (Note 4—Intangibles). The severance payable was settled following the completion of the Arrangement and no amounts were owing as at September 30, 2018.